Suchergebnisse - "Pinato, David J"

PubPharm (284)

41

Antibiotic Therapy : The Cornerstone of Iatrogenic Resistance to Immune Checkpoint Inhibitors

enthalten in: Journal of clinical oncology : official journal of the American Society of Clinical Oncology | 2023

von Pinato, D. | Cortellini, A.

CommentOn: J Clin Oncol. 2023 Jun 10;41(17):3122-3134. - PMID 36827626

42

Pandemic Phase-Adjusted Analysis of COVID-19 Outcomes Reveals Reduced Intrinsic Vulnerability and Substantial Vaccine Protection From Severe Acute Respiratory Syndrome Coronavirus 2 in Patients With Breast Cancer

enthalten in: Journal of clinical oncology : official journal of the American Society of Clinical Oncology | 2023

von Tagliamento, M. | Gennari, A. | Lambertini, M. | +50

43

Efficacy and safety of frontline systemic therapy for advanced HCC : A network meta-analysis of landmark phase III trials

enthalten in: JHEP reports : innovation in hepatology | 2023

von Fulgenzi, C. | Scheiner, B. | Korolewicz, J. | +10

44

SARS-CoV-2 omicron (B.1.1.529)-related COVID-19 sequelae in vaccinated and unvaccinated patients with cancer : results from the OnCovid registry

enthalten in: The Lancet. Oncology | 2023

von Cortellini, A. | Tabernero, J. | Mukherjee, U. | +126

45

Second-line treatment outcomes after progression from first-line chemotherapy plus immunotherapy in patients with advanced non-small cell lung cancer

enthalten in: Lung cancer (Amsterdam, Netherlands) | 2023

von Auclin, E. | Benitez-Montanez, J. | Tagliamento, M. | +24

46

Impact of body mass index in patients receiving atezolizumab plus bevacizumab for hepatocellular carcinoma

enthalten in: Hepatology international | 2023

von Vithayathil, M. | D’Alessio, A. | Fulgenzi, C. | +32

47

Impact of body mass index in patients receiving atezolizumab plus bevacizumab for hepatocellular carcinoma

enthalten in: Hepatology international | 2023

von Vithayathil, M. | D’Alessio, A. | Fulgenzi, C. | +32

48

Impact of body mass index in patients receiving atezolizumab plus bevacizumab for hepatocellular carcinoma

enthalten in: Hepatology international | 2023

von Vithayathil, M. | D’Alessio, A. | Fulgenzi, C. | +32

49

PETAL protocol : a phase Ib study of pembrolizumab after transarterial chemoembolization in hepatocellular carcinoma

enthalten in: Future oncology (London, England) | 2023

von Fessas, P. | Scheiner, B. | D'Alessio, A. | +8

50

Progression patterns and therapeutic sequencing following immune checkpoint inhibition for hepatocellular carcinoma : An international observational study

enthalten in: Liver international : official journal of the International Association for the Study of the Liver | 2023

von Talbot, T. | D'Alessio, A. | Pinter, M. | +33

CommentIn: Liver Int. 2023 Mar;43(3):528-530. - PMID 36808694